Latest news
Amgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed? - simplywall.stsimplywall.st · Sat, 08 Aug 2026 11:36:47 GMTAmgen: The Market Is Underestimating Its Next Growth Phase (NASDAQ:AMGN) - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 14:51:07 GMTAmgen remains bullish on Repatha, axes obesity asset in 2Q report - FirstWord PHARMAFirstWord PHARMA · Wed, 05 Aug 2026 01:51:57 GMTAmgen Raises 2026 Sales Forecast After Strong Q2 Beat - Briefs FinanceBriefs Finance · Tue, 04 Aug 2026 20:07:57 GMTAmgen second-quarter sales rise 9%, profit tops Street view - ReutersReuters · Tue, 04 Aug 2026 20:07:03 GMTHow Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration - simplywall.stsimplywall.st · Fri, 31 Jul 2026 03:38:35 GMTAmgen’s Repatha receives positive CHMP opinion for broader cardiovascular use - Pharmaceutical Business review -Pharmaceutical Business review - · Thu, 30 Jul 2026 14:31:43 GMTEuropean Medicines Agency Supports Amgen's Repatha for Broader Use - Intellectia AIIntellectia AI · Wed, 29 Jul 2026 15:29:08 GMT